AIDS-associated Cryptococcus neoformans and Penicillium marneffei coinfection: A therapeutic dilemma in resource-limited settings

Clinical Infectious Diseases

Volumn 51, Issue 9, 2010, Pages

  Le, Thuy ^a,c   Chau, Tran Thi Hong ^b   Cuc, Ngo Thi Kim ^b   Lam, Pham Si ^a   Sieu, Tran Phu Manh ^b   Shikuma, Cecilia M ^c   Day, Jeremy N ^a  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; COTRIMOXAZOLE; FLUCONAZOLE; FLUCYTOSINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD CULTURE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CULTURE; CLINICAL DECISION MAKING; CLINICAL FEATURE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIXED INFECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE PLANNING; PENICILLIOSIS; PENICILLIUM MARNEFFEI; PRIORITY JOURNAL; THRUSH; VIET NAM; VOMITING;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CRYPTOCOCCUS NEOFORMANS; DEVELOPING COUNTRIES; DIAGNOSIS, DIFFERENTIAL; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MALE; MYCOSES; PENICILLIUM; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; VIETNAM;

EID: 77958601003     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656685     Document Type: Article

References (19)

1. Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet 1994; 344(8915):110-113.
2. Mwaba P, Mwansa J, Chintu C, et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001; 77(914):769-773. (Pubitemid 33116512)
3. Supparatpinyo K, Nelson KE, Merz WG, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother 1993; 37(11):2407-2411.
4. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337(1):15-21.
5. Sirisanthana T, Supparatpinyo K, Perriens J, Nelson KE. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 26(5):1107-1110.
6. Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137(4):239-250.
7. Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 1998; 339(24):1739-1743.
8. Viviani MA, Tortorano AM. Penicillium marneffei. In: Ajello L, Hay RJ, eds. Medical mycology. Topley and Wilson's microbiology and microbial infections. Vol 4. 9th ed. London: Edward Arnold, 1998:409-419.
9. Negroni R, Arechavala AI. Itraconazole: pharmacokinetics and indications. Arch Med Res 1993; 24(4):387-393.
10. Supparatpinyo K, Schlamm HT. Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients. Am J Trop Med Hyg 2007;77(2):350-353.
11. Bandettini R, Castagnola E, Calvillo M, et al. Voriconazole for cryptococcal meningitis in children with leukemia. J Chemother 2009; 21(1):108-109.
12. Schiller DS, Fung HB. Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther 2007; 29(9):1862-1886.
13. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005;56(4):745-755.
14. DeMuria D, Forrest A, Rich J, Scavone JM, Cohen LG, Kazanjian PH. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother 1993; 37(10): 2187-2192.
15. Menichetti F, Fiorio M, Tosti A. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22:838-840.
16. Longley N, Muzoora C, Taseera K, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008; 47(12):1556-1561.
17. Nussbaum JC, Jackson A, Namarika D, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 2010; 50(3):338-344.
18. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4(5):e5575.
19. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa. Clin Infect Dis 2010; 50(11):1532-1538.